קסרלטו 20 מג ישראל - עברית - Ministry of Health

קסרלטו 20 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

קסרלטו 20 מג ישראל - עברית - Ministry of Health

קסרלטו 20 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

הרספטין 440 מג I.V ישראל - עברית - Ministry of Health

הרספטין 440 מג i.v

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

אוגיברי 420 מג ישראל - עברית - Ministry of Health

אוגיברי 420 מג

dexcel ltd, israel - trastuzumab - trastuzumab 420 mg/vial - trastuzumab

הרספטין 600 מג5 מל S.C ישראל - עברית - Ministry of Health

הרספטין 600 מג5 מל s.c

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה להזרקה - trastuzumab 600 mg / 5 ml - trastuzumab

טאלץ 80 מג ישראל - עברית - Ministry of Health

טאלץ 80 מג

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

פרדקסה 110 ישראל - עברית - Ministry of Health

פרדקסה 110

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate

פרדקסה 110 ישראל - עברית - Ministry of Health

פרדקסה 110

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate

פרדקסה 150 ישראל - עברית - Ministry of Health

פרדקסה 150

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate

פרדקסה 150 ישראל - עברית - Ministry of Health

פרדקסה 150

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate